文献速递炎症性肠病

炎症性肠病患者SARS-CoV-2感染风险因素与COVID-19病程:VA医疗系统全国队列研究

Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System.
PubMed 文献 · Gut · 2021-03-22

中位随访10.7个月,649例(2.1%)感染,149例(0.5%)达复合结局。调整模型中,维多珠单抗(HR 1.70)和糖皮质激素(HR 1.60)与感染风险升高相关;激素亦与复合结局相关(sub-HR 1.90),未用药者复合结局风险亦升高(sub-HR 1.64)。

要点

  • 维多珠单抗与SARS-CoV-2感染风险升高相关(HR 1.70)。
  • 糖皮质激素与感染及COVID-19住院或死亡风险升高独立相关。
  • 除激素外,其他IBD药物未显示与重症COVID-19风险升高相关。

核心结论

  • 维多珠单抗和糖皮质激素与SARS-CoV-2感染风险升高相关。
  • 除糖皮质激素外,包括美沙拉秦在内的其他药物未与重症COVID-19风险升高相关。

研究设计与样本

  • 按疫情前IBD用药分类,采用生存分析研究药物与SARS-CoV-2感染及COVID-19住院或死亡复合结局的关联。

主要发现

  • 中位随访10.7个月,649例(2.1%)诊断SARS-CoV-2感染,149例(0.5%)达到复合次要结局。
  • 调整模型中,与单用美沙拉秦相比,维多珠单抗使用与感染显著相关(HR 1.70,95%CI 1.16–2.48,p=0.006)。
  • 与单用美沙拉秦相比,未使用IBD药物者复合次要结局风险升高(sub-HR 1.64,95%CI 1.12–2.42,p=0.01)。
  • 糖皮质激素使用独立关联SARS-CoV-2感染(HR 1.60,95%CI 1.23–2.09,p=0.001)和复合次要结局(sub-HR 1.90,95%CI 1.14–3.17,p=0.01)。
  • 除糖皮质激素外,其他IBD药物类别与复合次要结局无显著关联(各p>0.05)。

临床怎么用

  • 临床应关注使用维多珠单抗或糖皮质激素的IBD患者在COVID-19期间的感染风险。
  • 对未使用IBD药物的患者,需警惕COVID-19住院或死亡风险升高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our aim was to explore the risk of infection with all classes of inflammatory bowel disease (IBD) medications and the impact of these medications on the disease course in a nationwide cohort of patients with IBD. DESIGN: This was a retrospective national cohort study of patients with IBD in the Veterans Affairs Healthcare System. We categorised IBD medication use immediately prior to the COVID-19 pandemic and used survival analysis methods to study associations with SARS-CoV-2 infection, as well as a combined secondary outcome of COVID-19 hospitalisation or COVID-19-related mortality. RESULTS: The analytical cohort of 30 911 patients was primarily male (90.9%), white (78.6%) and with ulcerative colitis (58.8%). Over a median follow-up of 10.7 months, 649 patients (2.1%) were diagnosed with SARS-CoV-2 infection and 149 (0.5%) met the combined secondary outcome. In adjusted models, vedolizumab (VDZ) use was significantly associated with infection relative to mesalazine alone (HR 1.70, 95% CI 1.16 to 2.48, p=0.006). Patients on no IBD medications had increased risk of the combined secondary outcome relative to mesalazine alone (sub-HR 1.64, 95% CI 1.12 to 2.42, p=0.01), however, no other IBD medication categories were significantly associated with this outcome, relative to mesalazine alone (each p>0.05). Corticosteroid use was independently associated with both SARS-CoV-2 infection (HR 1.60, 95% CI 1.23 to 2.09, p=0.001) and the combined secondary outcome (sub-HR 1.90, 95% CI 1.14 to 3.17, p=0.01). CONCLUSION: VDZ and corticosteroid were associated with an increased risk of SARS-CoV-2 infection. Except for corticosteroids no medications including mesalazine were associated with an increased risk of severe COVID-19.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Khan N, Mahmud N, Trivedi C, et al. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System. Gut. 2021. PMID: 33753416. doi:10.1136/gutjnl-2021-324356

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。